THR 100

Drug Profile

THR 100

Alternative Names: Recombinant staphylokinase variant - Bharat Biotech; Sak42D; THR100

Latest Information Update: 12 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Leuven
  • Developer Bharat Biotech
  • Class Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myocardial infarction

Most Recent Events

  • 31 Aug 2011 Bharat Biotech completes a phase III trial in Myocardial infarction in India (NCT01305226)
  • 04 Feb 2010 Phase-III clinical trials in Myocardial infarction in India (IV)
  • 07 Sep 2007 Thrombogenics completes transfer of manufacturing technology to Bharat Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top